PRESS RELEASE – Disruptive Pharma raises 10 million SEK to further develop product candidate DPH008 for prostate cancer and to expand our new business area Technology Solutions.

Press Release / Pressmeddelande
Disruptive Pharma offentliggör utfall i företrädesemission av aktier 2025-07-01 =>

”The outcome of the rights issue, in which we received SEK 10 million, is a clear statement of strength and gives us good conditions to continue creating growth and shareholder value. We are grateful for the trust from our existing owners and are also pleased to welcome new shareholders who have chosen to become part of Disruptive Pharma. With a strengthened financial foundation, we can now focus fully on driving the development of our product candidate DPH008 for prostate cancer and expanding our new business area Technology Solutions. We look forward with confidence to the next step in our growth journey.” comments Peter Åsberg, CEO of Disruptive Pharma.